Celgene says Otezla falls short in added use study

July 9, 2014


— Shares of Celgene Corp. slipped in premarket trading Wednesday after the drugmaker said its psoriatic arthritis treatment Otezla missed the main goal of a late-stage study exploring an additional use.

The Summit, New Jersey, company said Otezla did not achieve a statistically significant improvement when compared to a placebo in a study of patients with a painful spinal joint disorder called ankylosing spondylitis. But the drug did show signs of effectiveness in patients with early stages of the disease who took Otezla for a longer period, so research is continuing.

Celgene said it planned to start another late-stage study after it does more data analysis. Late-stage research is the final phase before a drugmaker submits a potential treatment to regulators for approval.

The Food and Drug Administration approved Otezla in March as a treatment for psoriatic arthritis, which causes joint pain, stiffness and swelling in patients with psoriasis.

Otezla is not approved to treat ankylosing spondylitis in any country.

Celgene shares fell $1.42, or 1.4 percent, to $84.30 shortly before markets opened. The stock had only climbed about 1.5 percent so far this year, as of Tuesday's market close.

Join The Conversation

The Fresno Bee is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service